scholarly journals Antiangiogenic Drugs for Colorectal Cancer: Exploring New Possibilities

2013 ◽  
Vol 12 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Renata Ferrarotto ◽  
Paulo M. Hoff
Keyword(s):  
Colorectal Cancer ◽  
Antiangiogenic Drugs

scholarly journals Treatment with Antiangiogenic Drugs in Multiple Lines in Patients with Metastatic Colorectal Cancer: Meta-Analysis of Randomized Trials

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
R.-D. Hofheinz ◽  
U. Ronellenfitsch ◽  
S. Kubicka ◽  
A. Falcone ◽  
I. Burkholder ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Kinase Inhibitors ◽  
Meta Analysis ◽  
Progression Free Survival ◽  
Optimal Sequence ◽  
Primary Endpoints ◽  
Disease Stabilization ◽  
Antiangiogenic Drugs ◽  
The Impact

Background. In metastatic colorectal cancer (mCRC), continuing antiangiogenic drugs beyond progression might provide clinical benefit. We synthesized the available evidence in a meta-analysis.Patients and Methods. We conducted a meta-analysis of studies investigating the use of antiangiogenic drugs beyond progression. Eligible studies were randomized phase II/III trials. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints were the impact of continuing antiangiogenic drugs (i) in subgroups, (ii) in different types of compounds targeting the VEGF-axis (monoclonal antibodies versus tyrosine kinase inhibitors), and (iii) on remission rates and prevention of progression.Results. Eight studies (3,668 patients) were included. Continuing antiangiogenic treatment beyond progression significantly improved PFS (HR 0.64; 95%-CI, 0.55–0.75) and OS (HR 0.83; 95%-CI, 0.76–0.89). PFS was significantly improved in all subgroups with comparable HR. OS was improved in all subgroups stratified by age, gender, and ECOG status. The rate of patients achieving at least stable disease was improved with an OR of 2.25 (95%-CI, 1.41–3.58).Conclusions. This analysis shows a significant PFS and OS benefit as well as a benefit regarding disease stabilization when using antiangiogenic drugs beyond progression in mCRC. Future studies should focus on the optimal sequence of administering antiangiogenic drugs.

scholarly journals Second-line targeted therapy for metastatic colorectal cancer. Possibilities for choices

2018 ◽  
pp. 22-26
Author(s):  
L. V. Bolotina ◽  
A. D. Kaprin
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Second Line ◽  
Second Line Therapy ◽  
Biological Features ◽  
Line Therapy ◽  
Drug Regimens ◽  
Antiangiogenic Drugs ◽  
Effective Group ◽  
Line Drug

The most effective first-and subsequent line drug regimens for metastatic colorectal cancer (mCRC) suggest the inclusion of targeted drugs (TD). The choice of TD for the second-line therapy takes into account not only the biological features of the tumor and the general condition of the patient, but also the option of the previous line therapy, its effectiveness and toxicity. Treatment with anti-EGFR antibodies (AT) did not significant improve overall survival (OS) in comparison with chemotherapy in the secondline regimens, in contrast to antiangiogenic drugs. Among this group of MAT, aflibercept provides the best results in a selected group of patients (the highly effective group) and a controlled toxicity profile.

Antiangiogenic drugs currently used for colorectal cancer: What other pathways can we target to prolong responses?

2007 ◽  
Vol 20 (5) ◽  
pp. 307 ◽  
Author(s):  
G. Abbadessa ◽  
P. Vogiatzi ◽  
L. Rimassa ◽  
P.P. Claudio
Keyword(s):  
Colorectal Cancer ◽  
Antiangiogenic Drugs

scholarly journals How we treat metastatic colorectal cancer

ESMO Open ◽  
2020 ◽  
Vol 4 (Suppl 2) ◽  
pp. e000813
Author(s):  
Vincenzo De Falco ◽  
Stefania Napolitano ◽  
Susana Roselló ◽  
Marisol Huerta ◽  
Andrés Cervantes ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Colorectal Cancer ◽  
Survival Benefit ◽  
Treatment Algorithm ◽  
Growth Factor Receptor ◽  
Molecular Profile ◽  
Curative Intent ◽  
Antiangiogenic Drugs ◽  
Tumour Characteristics

Colorectal cancer is the second leading cause of cancer-related death worldwide. About 20% of patients suffer from metastatic disease at diagnosis, while about one-third of patients treated with curative intent relapsed. In these patients, an accurate staging allows to plan a treatment strategy within a multidisciplinary team in order to achieve predefined goals. Patient’s clinical features, tumour characteristics and molecular profile (RAS/BRAF and microsatellite instability (MSI) status) should be considered during the treatment choice. Combination of chemotherapy (fluoropyrimidines, oxaliplatin and irinotecan) plus biological agents (antiepidermal growth factor receptor or antiangiogenic drugs) in addition to surgery, could give a chance of cure in resectable or potentially resectable tumours. However, in never resectable tumours, disease control and prolonging survival should be the goal to achieve simultaneously with control of symptoms. In addition to standard therapies, especially in case of unresectable oligometastatic disease, several local ablative treatment are available. In later lines, when improving quality of life become predominant, regorafenib and trifluridine/tipiracil demonstrated survival benefit, while re-challenge therapies represent an option only in selected patients. In patients with BRAFV600E-mutant tumour or with MSI, new therapies showed survival gain and probably will be a new piece in the treatment algorithm.

scholarly journals Protracted inhibition of vascular endothelial growth factor signaling improves survival in metastatic colorectal cancer: A systematic review

2017 ◽  
Vol 5 (1) ◽  
pp. 18-26 ◽  
Author(s):  
Francesco Montagnani ◽  
Greta Di Leonardo ◽  
Mariasimona Pino ◽  
Simona Perboni ◽  
Angela Ribecco ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Meta Analysis ◽  
Therapeutic Effects ◽  
Extensive Literature ◽  
Growth Factor Signaling ◽  
Analysis Model ◽  
Hazard Ratios ◽  
Inverse Variance ◽  
Antiangiogenic Drugs

Abstract Clinical data suggest that beyond-progression, the blockade of angiogenesis is associated with improved survivals in colorectal cancer. We conducted a systematic review to investigate the therapeutic effects of antiangiogenic drugs administered as later lines of treatment in patients already progressed to a previous anti-VEGF based treatment. An extensive literature search was conducted. Hazard ratios (HR) for progression (PFS) and death (OS) were extracted. An inverse-variance meta-analysis model was implemented. 6 randomized controlled trials were retrieved, including 3407 patients, treated with different antiangiogenic drugs. All of them had progressed during or after a previous line of treatment with bevacizumab. Overall, both PFS (HR=0.63, P <0.001) and OS (HR=0.81, P < 0.001) were significantly increased with the use of antiangiogenic drug. No heterogeneity was observed despite different drugs. Protracted inhibition of the VEGF pathway is associated with a significant improvement of both PFS and OS, independently from the antiangiogenic agent used.

Deletion mapping on chromosome 6 in colorectal cancer associated with ulcerative colitis

2001 ◽  
Vol 120 (5) ◽  
pp. A121-A122
Author(s):  
T EZAKI ◽  
M WATANABE ◽  
S FUNAKOSHI ◽  
M NAGANUMA ◽  
T AZUMA ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Ulcerative Colitis ◽  
Deletion Mapping ◽  
Chromosome 6

Predicting adherence to colorectal cancer surveillance after plypectomy

2001 ◽  
Vol 120 (5) ◽  
pp. A602-A602
Author(s):  
S RAWL ◽  
S BLACKBURN ◽  
L HACKWARD ◽  
N FINEBERG ◽  
T IMPERIALE ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Surveillance ◽  
Colorectal Cancer Surveillance
Sign in / Sign up

Export Citation Format

Share Document